Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 210

Results For "old"

2413 News Found

Glenmark receives U.S. FDA approval for Ryaltris
Drug Approval | January 14, 2022

Glenmark receives U.S. FDA approval for Ryaltris

The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily


South Korea approves Novavax Covid-19 vaccine
Drug Approval | January 13, 2022

South Korea approves Novavax Covid-19 vaccine

Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea


Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’
Sustainability | January 13, 2022

Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’

The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People


Merck KGaA appoints Global R&D Head & CSO for healthcare business sector
People | January 13, 2022

Merck KGaA appoints Global R&D Head & CSO for healthcare business sector

Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer


Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021
News | January 12, 2022

Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021

This surpasses the number of approvals supported in 2020


Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
News | January 12, 2022

Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra

Ind-Ra expects revenue growth of over 12% in 2022.


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Moderna Covid-19 boosters after five-month interval: U.S. FDA
News | January 08, 2022

Moderna Covid-19 boosters after five-month interval: U.S. FDA

Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older


Covaxin booster dose study shows promising results
News | January 08, 2022

Covaxin booster dose study shows promising results

Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events